back to Directory

Cyclica (acquired by Recursion Pharmaceuticals)

Cyclica logo

Website
https://cyclicarx.com/
Founded
2013
Patents
5
Publications
16

Technologies

AI Companies (Drug Discovery)

Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of disease.

Our computational approach to polypharmacology is unique in the industry. We use a proteome-wide lens to evaluate multiple novel and rare on and off-target interactions simultaneously.

We’re also the only company of our kind that integrates science to advance molecules downstream. A structure-based view keeps our work accountable to biology, chemistry, physics, and genomics.

To learn more about Cyclica and how we partner, please visit www.cyclicarx.com

Cyclica. From molecule to medicine.

Posts Mentioning This Company

Top AI Drug Discovery Companies Transforming the Pharma Industry

Tech-First Companies Take the Lead in AI Drug Discovery

  
In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery. These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial intelligence, enhancing its technology-enabled drug discovery capabilities …

Technology Meets Biology in Canada

  
Over the past decade, Canada emerged as a promising global location for drug discovery and biotech business, especially when it comes to applying advanced technologies, such as artificial intelligence (AI) and quantum computing in life sciences.
Toronto Startups Develop AI for Drug Discovery

Toronto’s Blossoming AI-driven Drug Discovery Scene

  
Canada has established itself as a rapidly growing global hub for artificial intelligence (AI) innovation and commercialization. This roots deep into the history of early programs and funding provided by Canadian Institute for Advanced Research (CIFAR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) to such AI …

Major VC Rounds For AI-driven Biotechs in 2020

  
The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- according to data by PitchBook biopharma venture deals in 2020 are down roughly 16% compared to last year.  However, there is still a lot going on in drug discovery and …
Pharma Companies Race To Tackle Wuhan Coronavirus Outbreak

How Pharma Reacts To Wuhan Coronavirus Outbreak

  
UPDATE April 04. 2020. The number of confirmed cases of COVID19 approaches 1M globally. Since too many drug repurposing programs and vaccine development projects have been urgently initiated, we decided to summarize them in a separate post: A Running List Of COVID-19 Treatments And Vaccines In Development With this, we …
Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

  
Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is …